“Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) As Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s652. Accessed April 20, 2026. https://skin.dermsquared.com/skin/article/view/3926.